| Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on … S Johnson, V Lavergne, AM Skinner, AJ Gonzales-Luna, KW Garey, ... Clinical infectious diseases 73 (5), e1029-e1044, 2021 | 469 | 2021 |
| Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection AJ Gonzales-Luna, AO Olaitan, WJ Shen, A Deshpande, TJ Carlson, ... Open forum infectious diseases 8 (8), ofab365, 2021 | 23 | 2021 |
| Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review TA Eubank, AJ Gonzales-Luna, JG Hurdle, KW Garey Antibiotics 11 (2), 258, 2022 | 22 | 2022 |
| PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255 AJ Gonzales-Luna, TJ Carlson, KM Dotson, K Poblete, G Costa, ... Emerging Microbes & Infections 9 (1), 341-347, 2020 | 22 | 2020 |
| Ultrasensitive and quantitative toxin measurement correlates with baseline severity, severe outcomes, and recurrence among hospitalized patients with Clostridioides difficile … CD Alonso, CP Kelly, KW Garey, AJ Gonzales-Luna, D Williams, ... Clinical Infectious Diseases 74 (12), 2142-2149, 2022 | 21 | 2022 |
| Clostridioides difficile ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain TJ Carlson, D Blasingame, AJ Gonzales-Luna, F Alnezary, KW Garey Anaerobe 62, 102142, 2020 | 21 | 2020 |
| Clostridioides (Formerly Clostridium) difficile Infection During Hospitalization Increases the Likelihood of Nonhome Patient Discharge KR Reveles, KM Dotson, A Gonzales-Luna, D Surati, BT Endres, MJ Alam, ... Clinical Infectious Diseases 68 (11), 1887-1893, 2019 | 20 | 2019 |
| Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial KW Garey, J McPherson, AQ Dinh, C Hu, J Jo, W Wang, CK Lancaster, ... Clinical Infectious Diseases 75 (7), 1164-1170, 2022 | 17 | 2022 |
| Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection S Ke, NR Pollock, XW Wang, X Chen, K Daugherty, Q Lin, H Xu, ... Gut microbes 13 (1), 1935186, 2021 | 17 | 2021 |
| A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome … KW Garey, K Begum, C Lancaster, A Gonzales-Luna, D Bui, J Mercier, ... Journal of Antimicrobial Chemotherapy 75 (12), 3635-3643, 2020 | 17 | 2020 |
| Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile AO Olaitan, C Dureja, MA Youngblom, MA Topf, WJ Shen, ... Nature Communications 14 (1), 4130, 2023 | 16 | 2023 |
| Assessment of quality of life among patients with recurrent Clostridioides difficile infection treated with investigational oral microbiome therapeutic SER-109: secondary … KW Garey, J Jo, AJ Gonzales-Luna, B Lapin, A Deshpande, E Wang, ... JAMA Network Open 6 (1), e2253570-e2253570, 2023 | 16 | 2023 |
| Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection TJ Carlson, BT Endres, J Le Pham, AJ Gonzales-Luna, FS Alnezary, ... Open forum infectious diseases 7 (1), ofz552, 2020 | 16 | 2020 |
| Ridinilazole for the treatment of Clostridioides difficile infection TJ Carlson, BT Endres, E Bassères, AJ Gonzales-Luna, KW Garey Expert opinion on investigational drugs 28 (4), 303-310, 2019 | 16 | 2019 |
| Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains BT Endres, K Begum, H Sun, ST Walk, A Memariani, C Lancaster, ... Open forum infectious diseases 6 (2), ofz013, 2019 | 16 | 2019 |
| Emerging Options for the Prevention and Management of Clostridioides difficile Infection AJ Gonzales-Luna, TJ Carlson, KW Garey Drugs 83 (2), 105-116, 2023 | 14 | 2023 |
| Toxin A–Predominant Pathogenic Clostridioides difficile: A Novel Clinical Phenotype Q Lin, NR Pollock, A Banz, A Lantz, H Xu, L Gu, DN Gerding, KW Garey, ... Clinical Infectious Diseases 70 (12), 2628-2633, 2020 | 14 | 2020 |
| In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile K Begum, E Bassères, J Miranda, C Lancaster, AJ Gonzales-Luna, ... Antimicrobial Agents and Chemotherapy 64 (8), 10.1128/aac. 00522-20, 2020 | 13 | 2020 |
| Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies AJ Gonzales-Luna, TJ Carlson, KW Garey Gut Microbes 15 (1), 2223345, 2023 | 11 | 2023 |
| Antibiotic Treatment Pipeline for Clostridioides difficile Infection (CDI): A Wide Array of Narrow-Spectrum Agents TJ Carlson, AJ Gonzales-Luna Current Infectious Disease Reports 22, 1-11, 2020 | 11 | 2020 |
